The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene encoding the peroxisomal ABC transporter adrenoleukodystrophy protein (ALDP). X-ALD is characterized by the accumulation of very long-chain fatty acids (VLCFA; > or =C24) in plasma and tissues. In this manuscript we provide insight into the pathway underlying the elevated levels of C26:0 in X-ALD. ALDP transports VLCFacyl-CoA across the peroxisomal membrane. A deficiency in ALDP impairs peroxisomal beta-oxidation of VLCFA but also raises cytosolic levels of VLCFacyl-CoA which are substrate for further elongation. We identify ELOVL1 (elongation of very-long-chain-fatty acids) as the single elongase catalysing the synthesis of both saturated VLCFA (C26:0) and mono-unsaturated VLCFA (C26:1). ELOVL1 expression is not increased in X-ALD fibroblasts suggesting that increased levels of C26:0 result from increased substrate availability due to the primary deficiency in ALDP. Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0 and lowers C26:0 levels in X-ALD fibroblasts. Given the likely pathogenic effects of high C26:0 levels, our findings highlight the potential of modulating ELOVL1 activity in the treatment of X-ALD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ALDP deficiency in X-ALD has two major effects: 1) it impairs peroxisomal VLCFA beta-oxidation and 2) it raises cytosolic VLCFacyl-CoA levels [50].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“The synthesis of VLCFA (C26:0) is enhanced in X-ALD [56] and it requires the elongases ELOVL6 and ELOVL1 [50,51].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“It was recently demonstrated that the synthesis of C24:0 and C26:0 is carried out by the concerted action of ELOVL6 (C18:0-C22:0) and ELOVL1 (C24:0-C26:0) [50] (Fig. 2).”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“These data establish that ALDP transports VLCFacyl-CoA into peroxisomes”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0 and lowers C26:0 levels in X-ALD fibroblasts [50].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 5×
“The recent breakthrough in gene therapy is currently only applied to CCALD (Cartier et al, 2009).”
BackgroundInfluentialPutative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundFatty acid elongases in mammals: their regulation and roles in metabolism
JAKOBSSON, A., WESTERBERG, R., & JACOBSSON, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.01.004 · Cited by 936 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Elongation of long-chain fatty acids
Leonard, A. E., Pereira, S. L., Sprecher, H., & Huang, Y.-S. (2004) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00040-7 · Cited by 584 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundOh, C.-S., Toke, D. A., Mandala, S., & Martin, C. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17376 · Cited by 486 · cited 3×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundZhang, K., Kniazeva, M., Han, M., Li, W., Yu, Z., Yang, Z., Li, Y., Metzker, M. L., Allikmets, R., Zack, D. J., et al. (2001) · Nature Genetics · doi:10.1038/83817 · Cited by 453 · cited 2×
“It is expressed predominantly in retina, brain and sperm (Tvrdik et al, 2000; Vasireddy et al, 2007; Zhang et al, 2001).”
BackgroundPeters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
Background
Research works printed but not linked: 1
- Moser AB,Kreiter N,Bezman L,Lu S,Raymond GV,Naidu S,Moser HW(1999)Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls.Ann Neurol45:100‐110 · doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u
Cited by
Items 101–172 of 172
Monternier, P., Singh, J., Parasar, P., Theurey, P., DeWitt, S. H., Jacques, V., Klett, E. L., Kaur, N., Nagaraja, T. N., Moller, D. E., et al. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12510 · Cited by 16
“Although VLCFA catabolism is mostly mediated by peroxisomes, we speculate that increased OCR in response to PXL065 might enhance mitochondrial lipid oxidation and contribute to VLCFA lowering by driving catabolism of shorter chain length fatty acid precursors that are substrates for the elongase that catalyzes synthes…”
BackgroundInfluentialPeroxisomal defects in microglial cells induce a disease-associated microglial signature
Raas, Q., Tawbeh, A., Tahri-Joutey, M., Gondcaille, C., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Leoni, V., Bellanger, E., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1170313 · Cited by 16
“Elovl1, which encodes for the main enzyme responsible for C26:0 synthesis (Ofman et al., 2010), was found very weakly but significantly induced in all mutant genotypes.”
BackgroundHama, K., Fujiwara, Y., Takashima, S., Hayashi, Y., Yamashita, A., Shimozawa, N., & Yokoyama, K. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p119000325 · Cited by 16
“Introduction Very long-chain fatty acids (VLCFA) with no less than 24 carbons are endogenously synthesized through a fatty acid elongation process [1].”
Computational insight into structural basis of human ELOVL1 inhibition
Siddiqui, A. J., Kumar, V., Jahan, S., Alshahrani, M. M., Awadh, A. A. A., Siddiqui, M. A., Hamadou, W. S., Abdelgadir, A., Saxena, J., Badraoui, R., et al. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106786 · Cited by 18
van de Beek, M.-C., Dijkstra, I. M. E., & Kemp, S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6937-1_5 · Cited by 17
Self-citationTrompier, D., & Savary, S. (2013) · Colloquium Series on The Genetic Basis of Human Disease · doi:10.4199/c00075ed1v01y201303gbd004 · Cited by 19
Wu, C., Iwamoto, T., Igarashi, J., Miyajima, T., Hossain, M. A., Yanagisawa, H., Akiyama, K., Shintaku, H., & Eto, Y. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.06.004 · Cited by 18
Turk, B. R., Theda, C., Fatemi, A. S., & Moser, A. B. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.11.002 · Cited by 19
Evolution of adrenoleukodystrophy model systems
Ferrer, R. M., Heine, V. M., Kemp, S., & Engelen, M. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12357 · Cited by 14
“Expression of the seven human ELOVL enzymes in yeast revealed ELOVL1 as the single elongase that catalyzes the synthesis of both saturated VLCFA (C26:0) and monounsaturated VLCFA (C26:1) in humans.(20) Expression of ELOVL1 is not increased in ALD patient fibroblasts, indicating that elongation of VLCFAs is increased i…”
BackgroundSelf-citationPathology of the neurovascular unit in leukodystrophies
Zarekiani, P., Breur, M., Wolf, N. I., de Vries, H. E., van der Knaap, M. S., & Bugiani, M. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01206-6 · Cited by 17
Schackmann, M. J. A., Ofman, R., van Geel, B. M., Dijkstra, I. M. E., van Engelen, K., Wanders, R. J. A., Engelen, M., & Kemp, S. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.03.009 · Cited by 15
Self-citationWang, W., He, Q., Guo, Z., Yang, L., Bao, L., Bao, W., Xu, Z., Wang, Y., & Wang, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716440 · Cited by 14
“In a previous publication, ELOVL1 protein expression was reduced by 80% at six days using siRNA to knockdown ELOVL1 in X-linked adrenoleukodystrophy (X-ALD) fibroblasts [17].”
BackgroundGuo, Z., Wang, Y., Feng, X., Bao, C., He, Q., Bao, L., Hao, H., & Wang, Z. (2016) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.15.0660 · Cited by 13
“Human ELOVL1 is the functional orthologue of yeast ELO3 and this is in line with that of mouse ELOVL1 (Tvrdik et al., 2000; Ofman and Dijkstra, 2010).”
BackgroundPathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms
Parasar, P., Kaur, N., & Singh, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280151 · Cited by 12
“Knock down of ELOVL 1 has resulted in reduction of C26:0 concentration in X-ALD fibroblasts; however, its expression is unchanged in X-ALD fibroblasts [30].”
BackgroundShah, N., & Singh, I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9746-0 · Cited by 14
“In addition to the role of ABCD1 dysfunction, the biosynthesis of VLCFA by ELOVL1 (elongase) also reported to contribute to VLCFA load in X-ALD [31] indicating that ELOVL1 may F o l d c h a n g e”
BackgroundRevisiting the Pathogenesis of X-Linked Adrenoleukodystrophy
Bougnères, P., & Le Stunff, C. (2025) · Genes · doi:10.3390/genes16050590 · Cited by 11
Jaspers, Y. R. J., Meyer, S. W., Pras‐Raves, M. L., Dijkstra, I. M. E., Wever, E. J. M., Dane, A. D., van Klinken, J. B., Salomons, G. S., Houtkooper, R. H., Engelen, M., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100567 · Cited by 11
“3D, C26:0 in PC represents the combined abundance of all PC lipids containing C26:0.”
BackgroundInfluentialSelf-citationDong, L.-W., Xiao, J., Liu, S., Deng, G., Liao, Y.-C., Chu, B., Zhao, X., Song, B., & Luo, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2260-4 · Cited by 10
“…4C showed that the decreased fluorescence intensity in ABCD1-knockdown cells was completely rescued by HPCD. VLCFA accumulation is a prominent marker of X-ALD, and ELOVL1 (elongation of very-long-chain-fatty acids protein 1) is the elongase catalyzing the synthesis of VLCFA (Ofman et al., 2010).”
BackgroundNatarajan, A., Christopher, R., Netravathi, M., Bhat, M. D., & Chandra, S. R. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.059 · Cited by 10
Morita, M., Kawamichi, M., Shimura, Y., Kawaguchi, K., Watanabe, S., & Imanaka, T. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9701-1 · Cited by 10
“Microsomal fatty acid elongation”
BackgroundHematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy
Eichler, F., & Kuehl, J.-S. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90242-7.00018-3 · Cited by 8
Multi-omics characterization of the unsaturated fatty acid biosynthesis pathway in colon cancer.
Chen, L., Yang, C., Chen, S.-D., Zhou, Q., Wang, G., Cai, S., Li, W., & Luo, H. (2022) · PubMed · Cited by 8
Recent advances in understanding inherited disorders of keratinization
Zaki, T. D., & Choate, K. A. (2018) · F1000Research · doi:10.12688/f1000research.14514.1 · Cited by 7
“Thin-layer chromatography revealed decreased levels of ceramides with ≥ C 26 fatty acids 28 .”
BackgroundInfluentialLiu, X., Liu, Y., Cheng, H., Deng, Y., Xiong, X., & Qu, X. (2021) · Italian Journal of Animal Science · doi:10.1080/1828051x.2021.1872423 · Cited by 7
“Ofman et al. (2010) demonstrated that knockdown of ELOVL1 lowers C26:0 synthesis and C26:0 levels in X-linked adrenoleukodystrophy (X-ALD) fibroblasts, which provided ELOVL1 inhibition could be used as a therapeutic option for X-ALD.”
BackgroundABCD1 gene mutation in an Italian family with X-linkedadrenoleukodystrophy: case series
Mohn, A., Polidori, N., Aiello, C., Rizzo, C., Giannini, C., Chiarelli, F., & Cappa, M. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0125 · Cited by 9
Liu, M.-Y., Wang, Q., Li, J., Zhang, D., Mu, J.-H., & Shen, X. (2024) · Russian Journal of Genetics · doi:10.1134/s1022795424040070 · Cited by 6
“Elovl1 genes are characterized in humans, and the adjustment of Elovl1 activity has a potential therapeutic effect on X-linked adrenoleukodystrophy, which is considered a therapeutic target for skin disease [12].”
Shibata, Y., Matsushima, M., Matsukawa, T., Ishiura, H., Tsuji, S., & Yabe, I. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-00866-x · Cited by 7
Morita, M., Honda, A., Kobayashi, A., Watanabe, Y., Watanabe, S., Kawaguchi, K., Takashima, S., Shimozawa, N., & Imanaka, T. (2017) · JIMD Reports · doi:10.1007/8904_2017_32 · Cited by 7
“In ALD, ELOVL1 is thought to mainly be involved in the accumulation of saturated VLCFAs, because the accumulation of C26:0 was decreased by a silencing of the ELOVL1 gene in ALD fibroblasts (Ofman et al. 2010).”
BackgroundJang, J., Lee, J. W., Song, J., Kim, D., & Min, K. H. (2019) · ChemistryOpen · doi:10.1002/open.201800281 · Cited by 6
Lier, J., Ponleitner, M., Popp, D., Schäfer, L., Küstermann, F., Meigen, C., Kratzer, F., Janda, J., Okun, J. G., Jamra, R. A., et al. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70176 · Cited by 3
“Experimental evidence indicates that glucocorticoids up-regulate the generation of substrates of VLCFA biosynthesis [24–26].”
Mondal, A., Chakraborty, A., Nandi, S., Singh, V., Kamat, S. S., & Das, C. (2026) · Nature Communications · doi:10.1038/s41467-026-72138-9 · Cited by 3
C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy
Jaspers, Y. R. J., Dijkstra, I. M. E., Engelen, M., & Kemp, S. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109070 · Cited by 3
Self-citationTieu, J., Sahasrabudhe, S. A., Orchard, P. J., Cloyd, J. C., & Kartha, R. V. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15090 · Cited by 4
“It is indicated for progressive or recurrent cutaneous T-cell lymphoma.77,78 There are concerns of thrombocytopaenia and neutropaenia at higher doses but otherwise SAHA is generally welltolerated.77 SAHA has been considered in neurodegenerative diseases such as multiple sclerosis (MS), Huntington's Disease and X-ALD d…”
BackgroundInfluentialLeukodystrophies and Lysosomal Storage Disorders
Escolar, M. L., & Aldenhoven, M. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8357-1_4 · Cited by 3
Bhandari, S., & Choe, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811297-7.00019-6 · Cited by 5
Faust, P. L. (2018) · Wiley eBooks · doi:10.1002/9781119013112.ch31 · Cited by 3
Hama, K., Fujiwara, Y., Imai, K., Kusakabe, Y., Hayashi, Y., Takashima, S., Azuma, S., Kondo, M., Yamashita, A., Takita, R., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100973 · Cited by 3
“…cells, VLCFA-CoA is produced directly from long-chain fatty acyl-CoA such as C16:0-CoA, through fatty acid elongation reactions in X-ALD patients (3, 51), whereas exogenous very long-chain FFA need to be converted to VLCFA-CoA by long-chain acyl-CoA synthetases (ACSLs) or very long-chain…”
Zhang, L., Yu, Y. F., Liu, T., Li, C., Tan, L., & Wen, S. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03499-x · Cited by 2
Pkd1 Mutation Has No Apparent Effects on Peroxisome Structure or Lipid Metabolism
Terabayashi, T., Menezes, L. F., Zhou, F., Cai, H., Walter, P. J., Garraffo, H. M., & Germino, G. G. (2021) · Kidney360 · doi:10.34067/kid.0000962021 · Cited by 2
“A decrease in VLCFA oxidation also results in an increase in substrate for further fatty acid chain elongation [32].”
BackgroundHuo, J., Feng, L., Cheng, Y., Miao, Y.-L., Liu, W., Hou, M.-M., Zhang, H., Yang, C., Li, Y., Zhang, M., et al. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111072 · Cited by 1
“Elongation of the very long-chain fatty acid protein (ELOVL) family (ELOVL1 – 7) are integral membrane proteins responsible for the synthesis of 16 – 28 carbon very long-chain fatty acids (VLCFAs) in mammalian tissues (Schackmann et al., 2015; Ofman et al., 2010).”
Eberhart, T., Charles, K. N., Salumbides-Torres, B., Price, N., Fliesler, S. J., Faust, P. L., & Kovacs, W. J. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1636268 · Cited by 1
X-linked adrenoleukodystrophy; Recent Advances in Classification, Diagnosis and Management
정을식, 강훈철, & 고아라 (2016) · Annals of Child Neurology · doi:10.26815/jkcns.2016.24.3.71 · Cited by 1
X-linked adrenoleukodystrophy in Norway Clinical and epidemiological aspects
Horn, M. A. (2016) · NVA (Nasjonalt vitenarkiv) · Cited by 1
Human Cytomegalovirus Regulates Host Lipid Metabolism
Xi, Y. (2021) · UA Campus Repository (The University of Arizona) · Cited by 1
Baarine, M. (2010) · theses.fr (ABES) · doi:10.70675/7ab2bcc8z16d2z420cz92f9zb3fd52371382 · Cited by 1
Molecular Genetics of X‐linked Adrenoleukodystrophy
Kemp, S. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0024277
Self-citationChildhood Neurodegenerative Disorders
Nair, L. D. V. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch018
Klemp, H. G. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8875
Rodríguez‐Pascau, L., Vilalta, A., Cerrada, M., Traver, E., Forss‐Petter, S., Weinhofer, I., Bauer, J., Kemp, S., Pina, G., Pascual, S., et al. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.8.10
Self-citationNur-E-Jannat, S., & Ahmed, D. S. (2023) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20232118
Lipid metabolism in neurodegenerative diseases
Bogie, J. F. J., Guns, J., & Vanherle, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00008-5 · Cited by 1
Therapie der X-chromosomalen Adrenoleukodystrophie
Köhler, W. (2024) · DGNeurologie · doi:10.1007/s42451-024-00645-4
X-linked adrenoleukodystrophy/adrenomyeloneuropathy
Rizzo, W. B., & Baker, C. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00109-6
X-linked adrenoleukodystrophy: literature review, description of clinical cases
Alekseeva, V. A., Gavrichenko, A. V., Yakovlev, A. A., Sokolova, M. G., Barantsevich, E. R., & Abramova, A. P. (2025) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2025-32-2-100-112
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Figshare · doi:10.6084/m9.figshare.26699159
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Figshare · doi:10.6084/m9.figshare.26699156
Zierfuss, B., Buda, A., Villoria-González, A., Logist, M., Fabjan, J., Parzer, P., Battin, C., Vandersteene, S., Dijkstra, I. M. E., Waidhofer‐Söllner, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26555513
Self-citationYska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Figshare · doi:10.6084/m9.figshare.25506745
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Figshare · doi:10.6084/m9.figshare.25506610
Reun, J. L., Salvioli, Z., Croux, C., Esque, J., André, I., & Bordes, F. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02890-y
“Mutations in ELOVL4 are associated with Stargardt-like macular dystrophy [19], and defects in ELOVL1 are linked to neurological disorders such as X-linked adrenoleukodystrophy [20].”
Zhou, Y., Huang, X., Liu, X., Zhang, L., Huang, J., Zhao, J., Zhang, Y., Zhang, J., Gong, Y., Zhang, D., et al. (2026) · View · doi:10.1002/viw.20250199
Tsai, A. C., Lee, H.-T., Sanchez, B., Huang, Y.-R., Krysinski, S., Zalan, A., & Falsey, E. (2026) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2026.101305
Wu, W. H., Zhan, D., Gao, Y., Jiang, Y., Pang, Q., Pei, Y., Wang, J., Li, Y., Wang, Y., Huang, S., et al. (2026) · Biology Direct · doi:10.1186/s13062-026-00790-8
“ELOVL1 is a crucial fatty acid elongase that facilitates the production of VLCFAs, playing an essential role in lipid metabolism [10].”
Molina-Blas, S., Pujalte, S. P., Álvarez, A. M., Álvarez‐Ríos, A. I., Cabello, B. M., Moreno, C. N., Gómez-Gila, A. L., Fuentes, E., Venegas-Moreno, E. M., & Delgado‐Pecellín, C. (2026) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70269
“While some studies have reported associations between VLCFA-derived biomarkers and clinical phenotypes [23, 24], more recent evidence has highlighted stronger correlations for alternative lipid biomarkers, such as C26:0-LPC, particularly in relation to CALD [13, 14].”
Hekmatpou, P., Bayat, S., Sadati, S., & Gholami, M. (2026) · مجله دانشگاه علوم پزشکی اراک · doi:10.66224/jams.28.6.459
The complex lipidome as a driver of tissue-specific pathology in adrenoleukodystrophy
Kemp, S., Engelen, M., & Jaspers, Y. R. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00975-9 · Cited by 1
“VLCFA synthesis primarily depends on long-chain fatty acid elongation, which is mainly regulated by ELOVL1 [58, 59].”
InfluentialSelf-citationAnalysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy
Ponleitner, M., Lier, J., Bracoud, L., Kabak, E. G., Thompson, R. E., McLaughlin, H. G., Delmonte, A., Cajgfinger, T., Schäfer, L., Awissus, C., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218407
BindingDB (2023) · UC San Diego · doi:10.7270/q2ff3x7k
BindingDB Entry 50016617: Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.
BindingDB (2023) · UC San Diego · doi:10.7270/q22r3wpp
Zhou, J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Kemp, Stephan
- Venue
- EMBO Molecular Medicine
- Published
- 2010-02-17
- Volume
- 2
- Issue
- 3
- Pages
- 90-97
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3377275
- OpenAlex
- W2111220794
- Cited by
- 170
- References
- 38
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 14 · 2023: 8 · 2022: 8 · 2021: 20 · 2020: 11 · 2019: 8 · 2018: 10 · 2017: 5 · 2016: 13 · 2015: 9 · 2014: 12 · 2013: 11 · 2012: 10
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Leukodystrophy Association (2006‐031I4, 2008‐001C4)
- Netherlands Organization for Scientific Research (016.086.328)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- X-linked adrenoleukodystrophy, ELOVL1, very long chain fatty acids, ABCD1, ALDP, peroxisomal beta-oxidation, fibroblasts, therapeutic target
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Fatty Acid Elongases, Acetyltransferases, Adrenoleukodystrophy, Fatty Acids, Homeostasis, Humans, ATP-Binding Cassette Transporters, Peroxisomes, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.